Funder
University of Western Ontario Schulich School of Medicine & Dentistry
Reference36 articles.
1. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy;Noris;Blood,2014
2. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome;Caprioli;Blood,2006
3. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome;Legendre;N Engl J Med,2013
4. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome;Greenbaum;Kidney Int,2016
5. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial;Fakhouri;Am J Kidney Dis,2016